vs
Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and FITLIFE BRANDS, INC. (FTLF). Click either name above to swap in a different company.
FITLIFE BRANDS, INC. is the larger business by last-quarter revenue ($25.9M vs $906.0K, roughly 28.6× Mind Medicine (MindMed) Inc.). FITLIFE BRANDS, INC. runs the higher net margin — 6.3% vs -2634.0%, a 2640.3% gap on every dollar of revenue. On growth, FITLIFE BRANDS, INC. posted the faster year-over-year revenue change (72.6% vs -16.1%).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
FitLife Brands, Inc. is a health and wellness firm developing, marketing and distributing premium nutritional supplements, sports nutrition products and weight management solutions. It serves North American fitness enthusiasts, athletes and health-focused consumers via retail and e-commerce channels.
DFTX vs FTLF — Head-to-Head
Income Statement — Q4 2023 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $906.0K | $25.9M |
| Net Profit | $-23.9M | $1.6M |
| Gross Margin | — | 34.5% |
| Operating Margin | -2450.8% | 8.8% |
| Net Margin | -2634.0% | 6.3% |
| Revenue YoY | -16.1% | 72.6% |
| Net Profit YoY | -386.7% | -20.8% |
| EPS (diluted) | $-0.58 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $25.9M | ||
| Q3 25 | — | $23.5M | ||
| Q2 25 | — | $16.1M | ||
| Q1 25 | — | $15.9M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $16.0M | ||
| Q2 24 | — | $16.9M | ||
| Q1 24 | — | $16.5M |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $921.0K | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $2.0M | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $2.6M | ||
| Q1 24 | — | $2.2M |
| Q4 25 | — | 34.5% | ||
| Q3 25 | — | 37.2% | ||
| Q2 25 | — | 42.8% | ||
| Q1 25 | — | 43.1% | ||
| Q4 24 | — | 41.4% | ||
| Q3 24 | — | 43.8% | ||
| Q2 24 | — | 44.8% | ||
| Q1 24 | — | 44.0% |
| Q4 25 | — | 8.8% | ||
| Q3 25 | — | 9.9% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 18.6% | ||
| Q4 24 | — | 19.2% | ||
| Q3 24 | — | 19.9% | ||
| Q2 24 | — | 21.7% | ||
| Q1 24 | — | 20.4% |
| Q4 25 | — | 6.3% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 10.8% | ||
| Q1 25 | — | 12.7% | ||
| Q4 24 | — | 13.8% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | — | 15.5% | ||
| Q1 24 | — | 13.1% |
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.09 | ||
| Q2 25 | — | $0.18 | ||
| Q1 25 | — | $0.20 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.27 | ||
| Q1 24 | — | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $78.1M | $43.6M |
| Total Assets | $124.5M | $106.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $46.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $13.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $16.5M |
| Q4 25 | — | $43.6M | ||
| Q3 25 | — | $41.9M | ||
| Q2 25 | — | $40.9M | ||
| Q1 25 | — | $38.9M | ||
| Q4 24 | — | $36.1M | ||
| Q3 24 | — | $34.2M | ||
| Q2 24 | — | $31.9M | ||
| Q1 24 | — | $29.4M |
| Q4 25 | — | $106.3M | ||
| Q3 25 | — | $110.0M | ||
| Q2 25 | — | $62.8M | ||
| Q1 25 | — | $62.2M | ||
| Q4 24 | — | $58.5M | ||
| Q3 24 | — | $58.6M | ||
| Q2 24 | — | $57.3M | ||
| Q1 24 | — | $55.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.11× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.36× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.56× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.6M | $244.0K |
| Free Cash FlowOCF − Capex | — | $239.0K |
| FCF MarginFCF / Revenue | — | 0.9% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $244.0K | ||
| Q3 25 | — | $3.7M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | — | $957.0K | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $1.6M | ||
| Q1 24 | — | $5.0M |
| Q4 25 | — | $239.0K | ||
| Q3 25 | — | $3.7M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $5.0M |
| Q4 25 | — | 0.9% | ||
| Q3 25 | — | 15.6% | ||
| Q2 25 | — | 7.4% | ||
| Q1 25 | — | 14.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 30.4% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 3.99× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 1.15× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | 0.96× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 2.33× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
